MREO

Mereo BioPharma Group plc

Nasdaq · Pharmaceutical Preparations · Inc. X0 · CIK 0001719714

$0.3057 +0.23% $47.3M

5 Institutional Exits

Vol

Market Cap$47.3M

Cap SizeNano Cap

Analyst ConsensusStrong Buy (71%)

Inst. Holders5 funds

Inst. Value$841.9K

Inst. Activity1 buys / 5 sells

Reddit Sentiment75° Bullish

SEC Reports1

Press Releases1

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. X0·CIK 0001719714·Prev Close $0.3050

Recent Activity

Jun 2, 2026 short_volume

Short Volume: MREO — 60.3% short (3.0M / 5.0M)

Short: 3,027,630 | Exempt: 376,275 | TRF Vol: 5,019,059 | Short Ratio: 60.3% | Off-exchange volume (

May 12, 2026 SEC

Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated

PRESS-RELEASE — Impact 6/10

Feb 26, 2026 Insider

Jacquet Pierre sold 66,000 shares

Director @ $0.00 ($0.00)

Feb 26, 2026 Insider

Jacquet Pierre sold 106,848 shares

Director @ $0.00 ($0.00)

Feb 26, 2026 Insider

Bender Jeremy sold 66,000 shares

Director @ $0.00 ($0.00)

Inst.

MORGAN STANLEY — TRIM

1,273,785 shares ($530.8K)

Inst.

TWO SIGMA INVESTMENTS, LP — TRIM

525,125 shares ($218.8K)

Mar 19, 2026 Press

Mereo BioPharma reported its 2025 financial results, showing a narrower net loss of $41.9 million compared to $43.3 mill

Impact 6/10

Price Targets

$1.73 +464.4% upside Strong Buy

Current $0.3057 Low $0.4965 Median $1.48 High $2.97 6 analysts

$0.4965 $2.97

Analyst Ratings

Buy71% buy · 14 analysts

5Strong Buy

5Buy

4Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
May 12, 2026	BTIG	REITERATE	Buy → Buy
Mar 23, 2026	JP Morgan	DOWNGRADE	Overweight → Neutral
Jan 16, 2026	BTIG	REITERATE	Buy → Buy
Jan 13, 2026	Needham	MAINTAIN	Buy → Buy
Dec 30, 2025	Jefferies	DOWNGRADE	Buy → Hold

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.01	$-0.01 — $0.00	62% YoY	5
Next Q	$-0.01	$-0.01 — $-0.01	8% YoY	5
Current FY	$-0.03	$-0.04 — $-0.02	25% YoY	5
Next FY	$-0.03	$-0.04 — $0.01	-0% YoY	6

Latest Reports

BEARISH PRESS-RELEASE 6/10

Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated

May 12, 2026

MIXED Press 6/10

Mereo BioPharma reported its 2025 financial results, showing a narrower net loss of $41.9 million compared to $43.3 mill

Mar 19, 2026

Top Institutional Holders

Fund	Value	Move
MORGAN STANLEY	$530.8K	TRIM
TWO SIGMA INVESTMENTS, LP	$218.8K	TRIM
RENAISSANCE TECHNOLOGIES LLC	$81.0K	TRIM
BANK OF AMERICA CORP	$10.6K	NEAR_EXIT
WELLS FARGO & COMPANY/MN	$724.00	DOUBLED

Recent Insider Trades

Date	Insider	Type	Value
Feb 26, 2026	Jacquet Pierre	A	$0.00
Feb 26, 2026	Jacquet Pierre	A	$0.00
Feb 26, 2026	Bender Jeremy	A	$0.00
Feb 26, 2026	Bender Jeremy	A	$0.00
Feb 26, 2026	PAKIANATHAN DEEPIKA	A	$0.00

Reddit Sentiment

75°

Bullish

Bearish Neutral Bullish

4 mentions 4 bullish 0 bearish

5 institutional holders with $841.9K total value (2,020,510 shares) as of 2025-Q4. Top holders: MORGAN, TWO, RENAISSANCE. Net selling activity: 5 institutions trimmed/exited vs 1 added.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	MORGAN STANLEY	1,273,785	$530.8K	63.0%	TRIM -61.9%
2	TWO SIGMA INVESTMENTS, LP	525,125	$218.8K	26.0%	TRIM -51.7%
3	RENAISSANCE TECHNOLOGIES LLC	194,371	$81.0K	9.6%	TRIM -67.1%
4	BANK OF AMERICA CORP /DE/	25,492	$10.6K	1.3%	NEAR_EXIT -94.2%
5	WELLS FARGO & COMPANY/MN	1,737	$724.00	0.1%	DOUBLED +655.2%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
MORGAN STANLEY	TRIM	3,346,347	1,273,785	-61.9%	$530.8K	2025-Q4
TWO SIGMA INVESTMENTS, LP	TRIM	1,088,096	525,125	-51.7%	$218.8K	2025-Q4
RENAISSANCE TECHNOLOGIES LLC	TRIM	590,871	194,371	-67.1%	$81.0K	2025-Q4
BANK OF AMERICA CORP /DE/	NEAR_EXIT	438,622	25,492	-94.2%	$10.6K	2025-Q4
WELLS FARGO & COMPANY/MN	DOUBLED	230	1,737	+655.2%	$724.00	2025-Q4
FMR LLC	EXIT	1,454,900	0	-100.0%	$0.00	2025-Q4
MORGAN STANLEY	DOUBLED	785,377	3,346,347	+326.1%	$6.9M	2025-Q3
TWO SIGMA INVESTMENTS, LP	ADD	659,158	1,088,096	+65.1%	$2.2M	2025-Q3
UBS Group AG	DOUBLED	373,505	970,667	+159.9%	$2.0M	2025-Q3
RENAISSANCE TECHNOLOGIES LLC	TRIM	1,480,471	590,871	-60.1%	$1.2M	2025-Q3
FMR LLC	ADD	759,100	1,478,500	+94.8%	$4.0M	2025-Q2
MORGAN STANLEY	TRIM	2,179,642	785,377	-64.0%	$2.1M	2025-Q2
TWO SIGMA INVESTMENTS, LP	DOUBLED	245,206	659,158	+168.8%	$1.8M	2025-Q2
UBS Group AG	TRIM	932,021	373,505	-59.9%	$1.0M	2025-Q2
WELLS FARGO & COMPANY/MN	NEAR_EXIT	1,230	230	-81.3%	$622.00	2025-Q2
MORGAN STANLEY	TRIM	3,554,234	2,179,642	-38.7%	$4.9M	2025-Q1
UBS Group AG	TRIM	2,648,140	932,021	-64.8%	$2.1M	2025-Q1
FMR LLC	NEW	—	759,100	—	$1.7M	2025-Q1
TWO SIGMA INVESTMENTS, LP	DOUBLED	68,735	245,206	+256.7%	$551.7K	2025-Q1
WELLS FARGO & COMPANY/MN	DOUBLED	229	1,230	+437.1%	$2.8K	2025-Q1
MORGAN STANLEY	ADD	2,347,825	3,554,234	+51.4%	$12.4M	2024-Q4
UBS Group AG	NEW	—	2,648,140	—	$9.3M	2024-Q4
CITADEL ADVISORS LLC	ADD	260,558	495,150	+90.0%	$1.7M	2024-Q4
MORGAN STANLEY	DOUBLED	207,736	2,347,825	+1030.2%	$9.6M	2024-Q3

13 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Feb 26, 2026	Jacquet Pierre	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	Jacquet Pierre	Director	A	106,848	$0.00	$0.00
Feb 26, 2026	Bender Jeremy	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	Bender Jeremy	Director	A	117,533	$0.00	$0.00
Feb 26, 2026	PAKIANATHAN DEEPIKA	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	Jenkins Annalisa	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	WYZGA MICHAEL S	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	Jenkins Annalisa	Director	A	106,848	$0.00	$0.00
Feb 26, 2026	Yoskowitz Marc J	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	Yoskowitz Marc J	Director	A	96,163	$0.00	$0.00
Feb 26, 2026	Shames Daniel	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	Shames Daniel	Director	A	96,163	$0.00	$0.00
Feb 26, 2026	Ekblom Anders	Director	A	66,000	$0.00	$0.00
Feb 26, 2026	Ekblom Anders	Director	A	133,560	$0.00	$0.00
Feb 1, 2026	Fox Christine Ann	Chief Financial Officer	A	315,750	$0.00	$0.00
Feb 1, 2026	Lewicki John A.	Chief Scientific Officer	A	139,913	$0.00	$0.00
Feb 1, 2026	Scots-Knight Denise	Chief Executive Officer	A	1,035,000	$0.00	$0.00
Feb 1, 2026	Hughes-Wilson Alexandra	See Remarks	A	183,750	$0.00	$0.00
Feb 1, 2026	Sermon Charles	General Counsel	A	315,750	$0.00	$0.00

1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 6.0/10.

BEARISH PRESS-RELEASE 6/10

Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue n

May 12, 2026

MIXED 6/10

Mereo BioPharma reported its 2025 financial results, showing a narrower net loss of $41.9 million co

Mar 19, 2026

Current analyst consensus: Buy (71% buy). Based on 14 analysts: 5 strong buy, 5 buy, 4 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$1.73 mean target +464.4% upside Strong Buy (3.00)

$0.4965 Low $2.97 High

Metric	Value
Current Price	$0.3057
Target Low	$0.4965
Target Mean	$1.73
Target Median	$1.48
Target High	$2.97
# Analysts	6
Recommendation	Strong Buy (3.00)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.01	$-0.01	$0.00	62.5%	—	—	$0.0B	133.5%	5
Next Q 2026-09-30	$-0.01	$-0.01	$-0.01	7.9%	—	—	$0.0B	0.0%	5
Current FY 2026-12-31	$-0.03	$-0.04	$-0.02	24.8%	—	1↑ 1↓	$0.0B	133.7%	5
Next FY 2027-12-31	$-0.03	$-0.04	$0.01	-0.5%	—	1↑ 0↓	$0.0B	1567.3%	6

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.006
7d ago	$0.000	-0.006
30d ago	$0.000	-0.006
60d ago	$-0.004	-0.002
90d ago	$-0.004	-0.002

5 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 12, 2026	BTIG	REITERATE	Buy	Buy
Mar 23, 2026	JP Morgan	DOWNGRADE	Overweight	Neutral
Jan 16, 2026	BTIG	REITERATE	Buy	Buy
Jan 13, 2026	Needham	MAINTAIN	Buy	Buy
Dec 30, 2025	Jefferies	DOWNGRADE	Buy	Hold
Dec 29, 2025	BTIG	MAINTAIN	Buy	Buy
Dec 29, 2025	LifeSci Capital	DOWNGRADE	Outperform	Market Perform
Dec 22, 2025	Needham	REITERATE	Buy	Buy
Dec 18, 2025	BTIG	REITERATE	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	5	5	4	71%
May 1, 2026	5	5	4	71%
Apr 1, 2026	5	5	4	71%
Mar 1, 2026	5	6	3	79%
Feb 1, 2026	5	6	3	79%
Jan 1, 2026	5	6	3	79%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

75°

Bullish

Bearish Neutral Bullish

4 mentions 4 bullish 0 bearish 4 time periods

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Threads
May 29, 2026	1	60° Warm	1	1
May 29, 2026	1	60° Warm	1	1
May 27, 2026	1	60° Warm	1	1
May 27, 2026	1	60° Warm	1	1

Recent Reddit Threads

r/pennystocks Bullish 11d 9h ago

Brazil’s Largest Lithium Valley Land Position— Spark Energy Minerals. $SPRK.c at $0.04 on CSE (Canada.) Second drilling round assays pending. First drill results revealed shallow rare earths up to 33% MREO & Gallium from surface in all 5 maiden drill holes. REE's & Gallium crucial to AI build out.

▲ 1 💬 1 ⚡ 0.2

r/pennystocks Bullish 13d 21h ago

$SPRK.c, Spark Energy Minerals, at $0.04/$0.045 on the CSE (Canada.) Follow up assays pending. First assays revealed up to 33% MREO and Gallium from Surface.

▲ 1 💬 1 ⚡ 0.5

Jun 2, 2026

short_volume

Short Volume: MREO — 60.3% short (3.0M / 5.0M)

Short: 3,027,630 | Exempt: 376,275 | TRF Vol: 5,019,059 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)

May 21, 2026

short_volume

Short Volume: MREO — 55.2% short (0.4M / 0.8M)

Short: 432,854 | Exempt: 9,999 | TRF Vol: 784,061 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)

May 19, 2026

short_volume

Short Volume: MREO — 60.3% short (0.4M / 0.7M)

Short: 441,565 | Exempt: 2,000 | TRF Vol: 732,404 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)

May 15, 2026

short_volume

Short Volume: MREO — 65.7% short (0.4M / 0.6M)

Short: 367,275 | Exempt: 50 | TRF Vol: 559,331 | Short Ratio: 65.7% | Off-exchange volume (dark pool + OTC)

May 12, 2026

earnings

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage bi

May 11, 2026

earnings_calendar

MREO Q1 2026 Earnings Scheduled — 2026-05-11

Apr 23, 2026

short_volume

Short Volume: MREO — 59.2% short (0.4M / 0.7M)

Short: 434,016 | Exempt: 20,202 | TRF Vol: 733,648 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)

Apr 22, 2026

short_volume

Short Volume: MREO — 58.5% short (0.4M / 0.8M)

Short: 449,713 | Exempt: 0 | TRF Vol: 768,189 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)

Apr 15, 2026

short_volume

Short Volume: MREO — 55.4% short (1.7M / 3.1M)

Short: 1,688,796 | Exempt: 0 | TRF Vol: 3,050,140 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)

Apr 10, 2026

short_volume

Short Volume: MREO — 56.8% short (0.3M / 0.6M)

Short: 349,211 | Exempt: 0 | TRF Vol: 614,466 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)

Apr 9, 2026

short_volume

Short Volume: MREO — 56.1% short (0.3M / 0.5M)

Short: 284,836 | Exempt: 300 | TRF Vol: 508,107 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)

Mar 27, 2026

short_volume

Short Volume: MREO — 63.7% short (0.6M / 1.0M)

Short: 616,203 | Exempt: 635 | TRF Vol: 967,624 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)

Mar 23, 2026

earnings_calendar

MREO Q4 2025 Earnings After Market Close — 2026-03-23

Mar 19, 2026

earnings

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing